Study S000743

A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02075281
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 297
Start: 2014-02
Primary completion: 2015-01
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Obesity
Interventions: BIOLOGICAL:HM11260C; BIOLOGICAL:Placebo
Results posted: FALSE

Registered primary outcomes

Change from baseline in body weight at 20 weeks [20 weeks from baseline]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010056	Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. Pratley RE, BMJ open diabetes research & care	2022	Randomized trial	PMID 35042751 DOI	cites ClinicalTrials.gov:NCT02075281
R0048646	1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205 Richard E. Pratley, Diabetes	2019	Other	DOI	cites ClinicalTrials.gov:NCT02075281
R0048864	53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study Richard E. Pratley, Diabetes	2019	Other	DOI	cites ClinicalTrials.gov:NCT02075281